In retrospect, before the era of immunotherapy, clinical studies by Jinushi et al. demonstrated that cancer patients who developed anti-sMICA antibodies to clear sMIC during treatment with cancer vaccines or anti-CTLA-4 treatment, had better clinical responses and enhanced NK cell anti-tumor activity [21,56]. This evidence concerns the gene CTLA4 and cancer.